Protagonist Therapeutics, Inc (PTGX) Financials
Annual revenue, profitability and per-share results for Protagonist Therapeutics, Inc, as reported in SEC filings.
Revenue • FY2025
$46.02M
▼ 89.4%YoY
Net income • FY2025
-$130.15M
▼ 147.3%YoY
Diluted EPS • FY2025
-$2.05
▼ 148.5%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $46.02M | -$130.15M | — | -$2.05 | $56.08M | -343.6% | -89.4% |
| FY2024 | $434.43M | $275.19M | — | $4.23 | $182.8M | 58.2% | +624.1% |
| FY2023 | $60M | -$78.95M | — | -$1.39 | -$70.84M | -156.1% | +125.7% |
| FY2022 | $26.58M | -$127.39M | — | -$2.60 | -$108.93M | -494.2% | -2.8% |
Figures as reported in Protagonist Therapeutics, Inc's 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a PTGX filing.
Get an email when PTGX files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.